Pharmacotherapy for Cluster Headache
CNS Drugs, vol. 34, pp. 171–184
Abstract
Cluster headache is characterised by attacks of excruciating unilateral headache or facial pain lasting 15 min to 3 h and is seen as one of the most intense forms of pain. Cluster headache attacks are accompanied by ipsilateral autonomic symptoms such as ptosis, miosis, redness or flushing of the face, nasal congestion, rhinorrhoea, peri-orbital swelling and/or restlessness or agitation. Cluster headache treatment entails fast-acting abortive treatment, transitional treatment and preventive treatment. The primary goal of prophylactic and transitional treatment is to achieve attack freedom, although this is not always possible. Subcutaneous sumatriptan and high-flow oxygen are the most proven abortive treatments for cluster headache attacks, but other treatment options such as intranasal triptans may be effective. Verapamil and lithium are the preventive drugs of first choice and the most widely used in first-line preventive treatment. Given its possible cardiac side effects, electrocardiogram (ECG) is recommended before treating with verapamil. Liver and kidney functioning should be evaluated before and during treatment with lithium. If verapamil and lithium are ineffective, contraindicated or discontinued because of side effects, the second choice is topiramate. If all these drugs fail, other options with lower levels of evidence are available (e.g. melatonin, clomiphene, dihydroergotamine, pizotifen). However, since the evidence level is low, we also recommend considering one of several neuromodulatory options in patients with refractory chronic cluster headache. A new addition to the preventive treatment options in episodic cluster headache is galcanezumab, although the long-term effects remain unknown. Since effective preventive treatment can take several weeks to titrate, transitional treatment can be of great importance in the treatment of cluster headache. At present, greater occipital nerve injection is the most proven transitional treatment. Other options are high-dose prednisone or frovatriptan.
Authors 5
-
Roemer B. Brandt corresponding Aachen Department of Neurology, Leiden University Medical Center (LUMC) Neurology Department
Leiden University Medical Center · Alrijne Ziekenhuis
Affiliation as printed
Department of Neurology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. r.b.brandt@lumc.nl
Neurology Department, Alrijne Hospital, Leiderdorp, The Netherlands. r.b.brandt@lumc.nl
Department of Neurology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
-
Leiden University Medical Center
Affiliation as printed
Department of Neurology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
-
Joost Haan Aachen Department of Neurology, Leiden University Medical Center (LUMC) Neurology Department
Leiden University Medical Center · Alrijne Ziekenhuis
Affiliation as printed
Department of Neurology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
Neurology Department, Alrijne Hospital, Leiderdorp, The Netherlands
-
Leiden University Medical Center
Affiliation as printed
Department of Neurology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
-
Leiden University Medical Center
Affiliation as printed
Department of Neurology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
Cited by 62 stored of 64
Cited by patents worldwide 20 (Lens.org)
-
Psilocybin compositions, methods of making and methods of using the sameUS12721856B2 2026-09-01 Active
-
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useUS12668605B2 2026-06-30 Active
-
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useUS12662498B2 2026-06-23 Active
-
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useUS12643917B2 2026-06-02 Active
-
Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybinUS12611418B2 2026-04-28 Active
-
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useUS12459965B2 2025-11-04 Active
-
Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybinUS12447164B2 2025-10-21 Active
-
Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybinUS12433904B2 2025-10-07 Active
-
Methods of treating neurocognitive disorders, chronic pain and reducing inflammationUS12377112B2 2025-08-05 Active
-
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useUS12312375B2 2025-05-27 Active
-
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useUS11939346B2 2024-03-26 Active
-
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useUS11851451B2 2023-12-26 Active
-
Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybinUS11738035B2 2023-08-29 Active
-
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useUS11629159B2 2023-04-18 Active
-
Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybinUS11564935B2 2023-01-31 Active
-
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useUS11505564B2 2022-11-22 Active
-
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useUS11447510B2 2022-09-20 Active
-
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useUS11180517B2 2021-11-23 Active
-
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useUS11149044B2 2021-10-19 Active
-
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their useUS10954259B1 2021-03-23 Active